Outcome variable | Policy group | Model | Coefficient | DW | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline | Outpatient Prescription Incentive Program (OPIP) | Price cut (SPS) | February | AR(1) | ||||||||
ß 0 | ß 1 | ß 2 | ß 3 | ß 4 | ß 5 | ß 6 | ||||||
Costs (billion KRW) | Overall | AR | 29.982§ | 0.295§ | −0.984# | − 0.136† | − 4.384§ | 0.192† | −2.643§ | 0.282# | 1.98 | |
Reduced | AR | 23.738§ | 0.065† | 1.357§ | −0.185§ | −4.809§ | − 0.023 | − 1.858§ | 0.277# | 2.06 | ||
Constant | AR | 6.240§ | 0.229§ | −2.264§ | 0.049 | 0.384 | 0.211§ | −0.856§ | − 0.080 | 1.80 | ||
Utiliz-ation | DDDs (million) | Overall | AR | 79.447§ | 0.463§ | −0.556 | − 0.023 | −1.058 | − 0.114 | −6.344§ | 0.338* | 2.12 |
Reduced | AR | 70.638§ | 0.161† | 1.321 | −0.119 | −1.442 | − 0.340† | −5.002§ | 0.333* | 2.14 | ||
Constant | OLS | 8.794§ | 0.301§ | −1.792§ | 0.094* | 0.426 | 0.220§ | −1.370§ | – | 1.99 | ||
Number of patients | Overall | OLS | 1,408,058§ | 11,758§ | − 47643* | 1698 | 17,535 | − 2504 | −89,533§ | – | 1.95 | |
Reduced | OLS | 1,129,486§ | 4909§ | − 6604 | 532 | 7296 | −7523§ | −64,306§ | – | 2.07 | ||
Constant | AR | 278,489§ | 6820§ | −39,690§ | 1207 | 8751 | 4989§ | −26,186§ | −0.168 | 1.79 | ||
Costs per patient (KRW) | Overall | OLS | 43,492§ | 160§ | − 2149§ | − 163§ | −3380§ | 107* | − 1063§ | – | 1.86 | |
Reduced | OLS | 20,992§ | −30† | 1123§ | −145§ | −3670§ | 81§ | − 550§ | – | 1.96 | ||
Constant | AR | 22,455§ | 183§ | − 2800§ | −27 | 233 | 43 | − 499† | −0.485† | 2.12 | ||
DDDs per patient | Overall | AR | 94.160§ | 0.095# | 0.317 | −0.083 | −1.564 | − 0.010 | −2.610* | 0.224 | 2.12 | |
Reduced | AR | 62.535§ | −0.120§ | 1.330† | −0.090* | −1.416† | 0.056 | −1.384§ | 0.135 | 2.04 | ||
Constant | OLS | 31.594§ | 0.215§ | −0.934 | −0.0004 | 0.005 | −0.068 | −1.123# | – | 2.08 |